Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to determine whether the PD-1 inhibitor
(Programmed cell death protein 1) nivolumab improves premalignant bronchial dysplastic
lesions in subjects that are at high risk for the development of lung cancer, including those
with a prior smoking history, or history of lung cancer or head and neck cancer. The safety
and tolerability of nivolumab will also be studied.